Supernus Pharma Stock Price, News & Analysis

Supernus (Nasdaq: SUPN) reported Q3 2025 total revenues of $192.1 million, a 9% increase versus Q3 2024, driven by combined growth-product sales of $149.2 million (+52%). The company completed the Sage acquisition on July 31, 2025, recording $20.2 million of collaboration revenue from ZURZUVAE for approximately two months post-close. Key product performance: Qelbree $81.4M (+31%), GOCOVRI $40.8M (+15%), and ONAPGO $6.8M in its first full commercial quarter. Cash and marketable securities were approximately $281.2M at September 30, 2025. The company raised full-year 2025 revenue guidance and updated operating and adjusted operating earnings guidance to reflect stronger results through nine months of 2025.

Supernus Pharmaceuticals (Nasdaq: SUPN) expects to report third quarter 2025 financial and business results after market close on Tuesday, November 4, 2025. Management will host a conference call and webcast the same day at 4:30 p.m. ET with Jack Khattar, President and CEO, and Tim Dec, SVP and CFO, presenting prepared remarks followed by a Q&A session.

A live webcast will be available in the Events & Presentations section of the investor relations site at www.supernus.com/investors. Participants may pre-register to receive a dial-in number and personalized conference code; dial-in is recommended 15 minutes before the start. A replay will be posted on the investor site and remain available for 60 days after the live call.

Supernus Pharmaceuticals (Nasdaq: SUPN), a CNS-focused biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. Management will attend the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 18.

The company will participate in fireside chats at each event, with presentations scheduled for 8:00 a.m. ET, 8:45 a.m. ET, and 10:40 a.m. ET respectively. Live audio webcasts will be available on the company's website, with replays accessible for 60 days following each conference.

Supernus Pharmaceuticals (Nasdaq: SUPN) reported Q2 2025 financial results, highlighting strong performance in key products. Total revenues reached $165.5 million in Q2 2025, with flagship product Qelbree® achieving 31% growth to $77.6 million and GOCOVRI® growing 16% to $36.7 million.

The company completed the strategic acquisition of Sage Therapeutics on July 31, 2025, strengthening its CNS portfolio with ZURZUVAE®. Notable developments include the successful launch of ONAPGO™ in April 2025, with over 750 enrollment forms from 300+ prescribers. The company increased its 2025 revenue guidance to $670-$700 million, reflecting strong H1 performance and the Sage acquisition impact.

Supernus Pharmaceuticals (Nasdaq: SUPN) has completed its acquisition of Sage Therapeutics, strengthening its position in neuropsychiatric treatments. The deal includes ZURZUVAE®, the first FDA-approved oral medicine for postpartum depression, and a CNS discovery platform.

The transaction structure includes $8.50 per share in cash plus contingent value rights (CVRs) worth up to $3.50 per share tied to specific milestones. The acquisition garnered 58% shareholder approval with 36,313,509 shares tendered. Supernus expects annual cost synergies of up to $200 million and projects the acquisition to be accretive by 2026.

The deal adds collaboration revenue from ZURZUVAE (50% of U.S. net sales through Biogen partnership) and complements Supernus' existing portfolio including Qelbree®, ONAPGO™, and GOCOVRI®.

Supernus Pharmaceuticals (NASDAQ: SUPN) announced the expiration of the Hart-Scott-Rodino waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements.

The CVR milestones include: $0.50 for ZURZUVAE's first commercial sale in Japan by June 2026, $1.00 for U.S. sales exceeding $250M by 2027, $1.00 for U.S. sales over $300M by 2028, and $1.00 for U.S. sales surpassing $375M by 2030. The tender offer expires on July 30, 2025, after which Supernus plans to complete the acquisition through a merger, making Sage its wholly owned subsidiary.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec. The presentation will be available via webcast through the company's investor relations website, with a replay accessible for 60 days following the event.

Supernus Pharmaceuticals (SUPN) announced the acquisition of Sage Therapeutics for a total consideration of up to $795 million ($12.00 per share), comprising $8.50 per share in cash upfront and a CVR worth up to $3.50 per share. The deal includes ZURZUVAE, the first FDA-approved oral medicine for postpartum depression, which generated collaboration revenue of $36.1M in 2024 and $13.8M in Q1 2025. Through a partnership with Biogen, Supernus will receive 50% of ZURZUVAE's U.S. net revenue. The acquisition is expected to close in Q3 2025, promising cost synergies of up to $200M annually and significant accretion in 2026. The CVR includes milestones tied to ZURZUVAE sales targets ranging from $250M to $375M and Japanese market entry.

Supernus Pharmaceuticals (SUPN) is expanding its partnership with TV personality Jay Glazer and his wife Rosie in a new content series about ADHD and relationships. The four-part video series, launching on the All About ADHD YouTube channel in May 2025, explores how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment, has helped Jay manage his symptoms. The series aims to provide insights into the challenges and successes of couples affected by ADHD, with Jay sharing his experience using Qelbree and Rosie discussing her supporting role. The first episode, "Jay & Rosie Glazer's ADHD Story: Real Life, Real Change," is now available. Qelbree is approved for ADHD treatment in adults and children 6 years and older, with important safety information including potential increased risk of suicidal thoughts and actions.